THIS IS A SOLE / SINGLE SOURCE, NON-COMPETITIVE NOTICE. This notice of intent is not a request for competitive proposals. This sole/single source, non-competitive notice is prepared in accordance FAR Parts 5 and 13. This notice of intent is not a request for competitive proposals. FAR Part 6 – Competition Requirements, is not applicable to contracts awarded using the simplified acquisition procedures of FAR Part 13.106-(b) (1). This announcement constitutes the only notice; proposals are not being requested and a written solicitation will not be issued. The resultant acquisition will be conducted in accordance with FAR Part 13, simplified acquisition procedures and the resultant purchase order will include all applicable provisions and clauses in effect through the Federal Acquisition Circular FAC 05-33 (as of June 15, 2009). The intended procurement will be classified under North American Industry Classification System code 325414, and the business size standard is 500 . Market Research conducted by the Government in accordance with the Federal Acquisition Regulations (FAR) Part 10, Market Research, has determined that only Illumina Inc., can perform/provide the requisite supplies/services specified herein. THE NATIONAL INSTITUTES OF HEALTH (NIH), National Heart, Lung, and Blood Institute (NHLBI), Office of Acquisition (OA), on behalf of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) intends to procure Genomic DNA kits for research under these items research studies/clinical protocol: 99-AR-0004 for Molecular Basis of Primary Immunodeficiencies and Epigenomic Regulation of Mammalian Development and Differentiation on a sole source basis, with Illumina Inc., 9885 Towne Center Drive, San Diego, California 92121 1 73619-100 RXN GENOMIC DNA SAMPLE PREP OLLIGO ONLY KIT 2 73619-1 DGE SMALL RNA SAMPLE PREP KIT (1000980) 3 73619-CHIP-SEQ SAMPLE PREPARATION KIT 4 73619-1 PE SAMPLE PREP KIT 5 73619-MRNA-SEQ 8 SAMPLE PREP KIT 6 73619-1 PHIX CONTROL KIT V2 (10 LANES) 7 73619-10 SINGLE-READ CLUSTER GENERATION KIT V2-GA II 8 73619-36 CYCLE SEQUENCING KIT V3.0 9 73619- 1 PAIRED END CLUSTER GFENERATION KIT V2-GA II 10 73619- 1 DGE-SMALL RNA CLUSTER GENERATION KIT V2-GA II 11 73619- SHIPPING AND INSURANCE Background: This project will entail the use of Chromatin –Immunoprecipiation (ChIP-seq), RNA, and micro-RNA (RNA-Seq and micro-RNA-Seq) massively parallel sequencing on the Illumina GAIIx platform.In an effort to catalog all epigenetic marks in mammalian cells, the NIH recently launched the Epigenome Roadmap. This initiative supports the production of reference epigenome maps in a variety of primary human cells or cell lines. A major challenge in epigenetic research not covered by the Roadmap however is the elucidation of how individual histone modifications contribute to the establishment and maintenance of other epigenetic marks. Another important but unsolved question relates to how individual histone modifications regulate cell differentiation, from stem cells to fully differentiated states. Determining the physiological function of histone modifications in mammalian cells has been particularly difficult because genetic deletion of histone or DNA modifying enzymes nearly invariably results in embryonic lethality. We propose to address these questions by first mapping the epigenomes in human hematopoietic stem cells, B, T, NK, skeletal muscle and retinal pigment epithelial cells and identify intrinsic epigenomic features. We next propose to investigate the mechanisms that establish these epigenomes by deleting in those same cells critical histone modifying enzymes including PTIP, which trimethylates lysine 4 of histone H3 (H3K4me3), EZH2 (H3K27me3), TIP60/TRRAP (H4K16 acetylation) and SIRT1 (H4K16 deacetylation). By integrating this large amount of epigenomic data using statistics and bioinformatics models, we hope to uncover how the epigenome contributes to cell differentiation as well as any potential crosstalk between different epigenetic modifications, a critical issue that has not been addressed so far. The strength of our proposal is that it joins the efforts of multiple groups with documented expertise in the area of epigenetics to survey histone modifications and understand their role in cell differentiation using well-established biological models. Typically, there is little motivation to systemically compare and contrast lessons from diverse systems. As a trans-NIH initiative, this project will have the advantage of bringing together investigators with different expertise to consider issues that will likely supersede their individual efforts. This notice of intent is not a request for competitive proposals. The resulting acquisition will be entered into pursuant to the acquisition authority set forth in FAR 6.302-1 and 41 U.S.C. 253(c)(1) and HHSAR 306-302-1. Only one responsible source and no other supplies or services will satisfy agency requirements. The sole source determination is based on the need to continue on-going experiment; changing variable would disrupt the outcome of the experiment. Therefore an award to any other source is not feasible nor practical. Interested parties may identify their interest and capability to respond to the requirement or submit proposals. This notice of intent is not a request for competitive proposals. However, all proposals received within 10 days after publication of this synopsis will be considered by the Government. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. Inquires to this notice, referencing number NHLBI-PB-(AR) 2009-205-RCO may be submitted to the National Heart, Lung and Blood Institute, Office of Acquisition, Procurement Branch, 6701 Rockledge Drive, Suite 6144, Bethesda, Maryland 20892-7902, Attention: Rosie C. Owens, Contract Specialist. Response may be submitted electronically to
[email protected]. Faxes will not be accepted. Responses will only be accepted if dated on or before June 27, 2009; and 3:30pm, Eastern Standard Time signed by an authorized company representative.